Novavax, Inc. is a biotechnology company, which discovers, develops and commercializes vaccines to prevent serious infectious diseases. The Company offers a differentiated vaccine platform that combines a recombinant protein approach, advanced nanoparticle technology and its patented Matrix-M adjuvant to enhance the immune response. It has one commercial program, for vaccines to prevent COVID-19, which includes Nuvaxovid prototype COVID-19 vaccine (NVX-CoV2373 or prototype vaccine) and Nuvaxovid updated COVID-19 vaccine (NVX-CoV2601 or updated vaccine) (collectively, COVID-19 Vaccine). The Company is advancing the development of other vaccine candidates, including its COVID19-Influenza Combination (CIC) vaccine candidate and additional vaccine candidates. Its COVID-19 Vaccine and its other vaccine candidates incorporate the Companyâ€™s proprietary Matrix-M adjuvant to enhance the immune response and stimulate higher levels of functional antibodies and induce a cellular immune response.

Employees

749

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-03-16	10.10 $	-1.32%	2,012,794
26-03-13	10.24 $	-0.63%	2,859,278
26-03-12	10.30 $	-4.63%	3,609,707
26-03-11	10.80 $	+1.03%	5,184,858
26-03-10	10.69 $	+1.33%	3,609,630

Delayed Quote Nasdaq

More quotes

Income Statement and Estimates

More financial data

Analysis / Opinion

Novavax Surges on $1.2 Billion Sanofi Vaccine Deal

May 10, 2024 at 01:36 pm EDT

More analyses

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.24USD

Average target price

13.78USD

Spread / Average Target

+34.61%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Real-time Estimate Cboe BZX Other stock markets 01:50:42 2026-03-16 pm EDT			5-day change	1st Jan Change
10.08 ^USD	-1.56%		-4.41%	+50.07%

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM

Capitalization	1.67B 1.45B 1.32B 1.25B 2.28B 154B 2.37B 15.63B 6.21B 73.66B 6.26B 6.13B 266B	P/E ratio 2026 *	-28.7x	P/E ratio 2027 *	-31.5x
Enterprise value	1.89B 1.64B 1.49B 1.42B 2.58B 174B 2.68B 17.68B 7.03B 83.33B 7.08B 6.93B 301B	EV / Sales 2026 *	4.92x	EV / Sales 2027 *	8.03x
Free-Float	94.79%	Yield 2026 *	-	Yield 2027 *	-

Mar. 10	Novavax, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-10-2026 03:40 PM
Mar. 03	Novavax, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 02:30 PM
Feb. 26	Health Care Down Amid Mixed Earnings -- Health Care Roundup	DJ
Feb. 26	Novavax raises revenue forecast on boost from vaccine deals, shares soar	RE
Feb. 26	Keros Therapeutics, Inc. Announces Board Changes, Effective March 9, 2026	CI
Feb. 26	Novavax outlook 2026 adjusted total revenue $230 mln - $270 mln	RE
Feb. 26	Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals	RE
Feb. 26	Novavax, Inc., Q4 2025 Earnings Call, Feb 26, 2026
Feb. 26	Top Midday Gainers	MT
Feb. 26	Novavax, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025	CI
Feb. 26	Novavax Shares Jump After Swinging to Profit in Q4	MT
Feb. 26	Novavax raises revenue forecast on boost from vaccine deals, shares soar	RE
Feb. 26	Earnings Flash (NVAX) Novavax Posts Q4 Total Revenue $147.1M, vs. FactSet Est of $89.8M	MT

Nov. 11	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
Nov. 10	B. Riley Adjusts Price Target on Novavax to $16 From $18, Maintains Buy Rating	MT
25-08-20	Novavax: BofA downgrades stock
25-08-20	Novavax Faces 'Increasingly Murky' Outlook on Vaccine Uncertainties, BofA Securities Says	MT
25-08-20	BofA Downgrades Novavax to Underperform From Neutral, Adjusts Price Target to $7 From $9	MT

Novavax, Inc. Stock

Equities

NVAX

US6700024010

Biotechnology & Medical Research

Valuation: Novavax, Inc.

Chart: Novavax, Inc.

Latest news: Novavax, Inc.

Last Transcript: Novavax, Inc.

Analysts' recommendations: Novavax, Inc.

Press Releases: Novavax, Inc.

News in other languages: Novavax, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: Novavax, Inc.

ETFs: Novavax, Inc.

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

Income Statement and Estimates

Analysis / Opinion

Analysts' Consensus

Quarterly revenue - Rate of surprise

Feb. 26	Novavax to Participate in Upcoming Investor Conferences	PR
Feb. 26	Novavax: Q4 Earnings Snapshot	AQ
Feb. 26	Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights	PR
Feb. 19	Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026	PR
Jan. 20	Novavax Announces Entering into a License Agreement with Pfizer	PR

Feb. 26	USA-Les valeurs à suivre à Wall Street (actualisé)
Jan. 20	Accord de licence entre Novavax et Pfizer pour l'utilisation de l'adjuvant Matrix-M
Jan. 20	Novavax : Accord de licence entre Novavax et Pfizer pour l'utilisation de l'adjuvant Matrix-M
Jan. 20	USA-Les valeurs à suivre à Wall Street (actualisé)
Dec. 12	Wall Street : Les baisses de taux ne vendent plus du rêve

1 day	-1.56%
1 week	-4.41%
Current month	-0.54%
1 month	+16.59%
3 months	+54.20%
6 months	+17.82%
Current year	+50.07%

1 week	9.95	11.05
1 month	8.5	11.97
Current year	6.76	11.97
1 year	5.01	11.97
3 years	3.53	23.86
5 years	3.53	277.8
10 years	3.53	331.68

Manager	Title	Age	Since
John Jacobs CEO	Chief Executive Officer	59	2023-01-22
James Kelly DFI	Director of Finance/CFO	60	2021-08-15
Gale Smith CTO	Chief Tech/Sci/R&D Officer	-	-

Director	Title	Age	Since
Richard Douglas BRD	Director/Board Member	73	2010-08-05
Rachel King BRD	Director/Board Member	66	2018-10-31
David Mott BRD	Director/Board Member	60	2020-06-15

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
NOVAVAX, INC.	-1.56%	-4.41%	+20.35%	+68.93%	1.67B
LONZA GROUP AG	+0.27%	-3.29%	-13.88%	-10.15%	42.78B
BEONE MEDICINES AG	+1.51%	-4.40%	+9.02%	+28.56%	31.5B
CELLTRION, INC.	-2.68%	-5.88%	+11.77%	+44.44%	29.99B
IQVIA HOLDINGS INC.	-0.41%	-7.66%	-10.83%	-16.06%	27.65B
REVOLUTION MEDICINES, INC.	+4.12%	-0.80%	+152.98%	+345.10%	18.8B
ASCENDIS PHARMA A/S	+1.79%	-4.01%	+36.41%	+109.96%	13.87B
MEDPACE HOLDINGS, INC.	+0.61%	-5.09%	+39.17%	+149.18%	12.78B
EUROFINS SCIENTIFIC SE	-0.33%	-3.53%	+22.17%	-0.65%	12.39B
IONIS PHARMACEUTICALS, INC.	+1.55%	-3.85%	+111.25%	+107.03%	11.76B
Average	+0.52%	-3.89%	+37.84%	+82.63%	20.32B
Weighted average by Cap.	+0.50%	-4.55%	+25.80%	+62.21%

	2026 *	2027 *
Net sales	383M 334M 302M 289M 525M 35.4B 544M 3.59B 1.43B 16.94B 1.44B 1.41B 61.09B	245M 214M 194M 185M 336M 22.65B 348M 2.3B 914M 10.84B 921M 901M 39.09B
Net income	-57.9M -50.43M -45.66M -43.56M -79.24M -5.35B -82.16M -543M -216M -2.56B -217M -213M -9.22B	-54.43M -47.41M -42.93M -40.95M -74.49M -5.02B -77.24M -510M -203M -2.4B -204M -200M -8.67B
Net Debt	219M 191M 173M 165M 300M 20.22B 311M 2.05B 816M 9.67B 822M 804M 34.89B	303M 264M 239M 228M 415M 27.99B 430M 2.84B 1.13B 13.39B 1.14B 1.11B 48.31B